Investor Shelf

Artificial Intelligence at the Helm: Revolutionizing the Life Sciences Sector (EY)

Save
ReportEYFebruary 202568 pages102 min readOriginal source
Key number
US$97.1 billion
AI in medical devices projected market by 2028 p.8
Largest segment
US$16.49 billion
AI in pharmaceuticals expected by 2034 p.8

Summary

  • AI in the pharmaceuticals sector is expected to reach US$16.49 billion by 2034.p.8
  • AI in the medical devices segment is projected to reach US$97.1 billion by 2028.p.8
  • About 50% of CXOs in surveyed Indian life sciences organizations are already exploring GenAI actively, with budgets allocated or invested.p.12
  • About 75% of CXOs in surveyed Indian life sciences organizations confirmed AI has been instrumental in reducing costs and driving customer satisfaction.p.12
  • GenAI advancements in healthcare are driving about 13% improvement in labor efficiency.p.12
  • India invested approximately INR 10,300 crore in March 2024 in the IndiaAI Mission.p.18

Key insights

  1. AI in pharmaceuticals is expected to reach US$16.49 billion by 2034, driven by drug discovery, clinical trials and personalized healthcare.p.8
  2. AI in medical devices is projected to reach US$97.1 billion by 2028 on diagnostic tools, smart devices, wearables and surgical robotics.p.8
  3. Challenges to AI adoption fall into ethical, technical and operational categories.p.9
  4. AI maturity is categorized into three levels: foundational, innovative and transformational.p.9
  5. As of 2023, AlphaFold has predicted over 200 million protein structures.p.15
  6. The EU AI Act is among the regulations governing AI in life sciences in Europe, alongside GDPR.p.16
  7. India committed approximately INR 10,300 crore in March 2024 to the IndiaAI Mission.p.18

Topics and entities

Summary and figures generated from the document and checked automatically: every number shown appears on the cited page. The full document is available from the publisher. Publishers can request removal.